Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2807

1.

Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.

Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S.

J Immunol. 2006 Feb 1;176(3):1447-55.

PMID:
16424172
[PubMed - indexed for MEDLINE]
Free Article
2.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
[PubMed - indexed for MEDLINE]
3.

Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.

Schnell S, Young JW, Houghton AN, Sadelain M.

J Immunol. 2000 Feb 1;164(3):1243-50.

PMID:
10640737
[PubMed - indexed for MEDLINE]
Free Article
4.

Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.

Tanaka Y, Koido S, Ohana M, Liu C, Gong J.

J Immunol. 2005 Feb 1;174(3):1274-80.

PMID:
15661883
[PubMed - indexed for MEDLINE]
Free Article
5.

Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.

Kleindienst P, Brocker T.

J Immunol. 2003 Mar 15;170(6):2817-23.

PMID:
12626531
[PubMed - indexed for MEDLINE]
Free Article
7.

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.

Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J.

Blood. 2005 Mar 15;105(6):2465-72. Epub 2004 Nov 16.

PMID:
15546948
[PubMed - indexed for MEDLINE]
Free Article
8.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

PMID:
14764678
[PubMed - indexed for MEDLINE]
Free Article
9.

Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.

Dolan BP, Phelan TP, Ilkovitch D, Qi L, Wade WF, Laufer TM, Ostrand-Rosenberg S.

J Immunol. 2004 Jan 15;172(2):907-14.

PMID:
14707062
[PubMed - indexed for MEDLINE]
Free Article
10.

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.

Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R.

J Immunol. 2003 Dec 1;171(11):5940-7.

PMID:
14634105
[PubMed - indexed for MEDLINE]
Free Article
11.
12.
13.

Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.

J Immunol. 1999 Jan 1;162(1):144-51.

PMID:
9886380
[PubMed - indexed for MEDLINE]
Free Article
14.

Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.

Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.

Cancer Res. 2006 Jan 15;66(2):1147-54.

PMID:
16424052
[PubMed - indexed for MEDLINE]
Free Article
15.

Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.

Wang J, Saffold S, Cao X, Krauss J, Chen W.

J Immunol. 1998 Nov 15;161(10):5516-24.

PMID:
9820528
[PubMed - indexed for MEDLINE]
Free Article
16.

Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.

Zhou G, Ding ZC, Fu J, Levitsky HI.

J Immunol. 2011 Feb 15;186(4):2148-55. doi: 10.4049/jimmunol.1002917. Epub 2011 Jan 17.

PMID:
21242518
[PubMed - indexed for MEDLINE]
Free Article
17.

Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.

Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, Nouta J, Melief CJ, Verbeek JS, Ossendorp F.

J Immunol. 2006 Apr 15;176(8):4573-80.

PMID:
16585547
[PubMed - indexed for MEDLINE]
Free Article
18.

Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.

van Bergen J, Camps M, Offringa R, Melief CJ, Ossendorp F, Koning F.

Cancer Res. 2000 Nov 15;60(22):6427-33.

PMID:
11103809
[PubMed - indexed for MEDLINE]
Free Article
19.

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.

Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2007 May;56(5):601-13. Epub 2006 Sep 8.

PMID:
16960693
[PubMed - indexed for MEDLINE]
20.

Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies.

Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B.

J Immunol. 2002 Mar 1;168(5):2154-62.

PMID:
11859101
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk